Ovarian cancer, the 5th leading cause of cancer deaths in the U.S., is one of the deadliest gynecologic malignancies due to its mild early symptoms, often leading to late detection. This edition of our Guidelines+ Monograph series explores niraparib (brand name Zejula) from GlaxoSmithKline (GSK), a once-daily oral (PO) PARP inhibitor. It’s FDA-approved as a […]
The opioid crisis continues to be a major public health issue, with overdose rates still rising in many areas, particularly due to the increasing prevalence of synthetic opioids like fentanyl. This edition of our Guidelines+ Monograph series will be dedicated to International Overdose Awareness Day, a day on August 31st of each year dedicated to […]
In this edition of our Guidelines Monographs Series, we will be taking a look at AstraZeneca’s medication dapagliflozin, brand name Farxiga. Initially approved in 2014, Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, provided to individuals with diabetes, heart disease, or kidney disease to improve their outcomes. This Guidelines+ Monograph will take a deeper dive […]
In this edition of our Guidelines+ Monographs Series, we will be taking a look at Bristol-Myers Squibb’s medication apixaban, brand name Eliquis. Initially approved in 2012, Eliquis is a factor Xa inhibitor, an anticoagulant used to prevent stroke and systemic embolism in nonvalvular atrial fibrillation, and to treat deep vein thrombosis (DVT) and pulmonary embolism […]